Transplant Trial Watch
Transplant International · 2024
DOI: 10.3389/ti.2024.13746 ↗Kurz gefasst
Editorial in der Zeitschrift Transplant International, 2024. Verfasst von John M O'Callaghan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplant Surgery, University Hospitals Coventry & Warwickshire, Coventry, United Kingdom. Hauptthemen laut MEDLINE: Immunosuppressive Agents. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch. The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. This page of Transplant International offers commentaries on methodological issues and clinical implications on two articles of particular interest from the CET Transplant Trial Watch monthly selection. For all high quality evidence in solid organ transplantation, visit the Transplant Library: www.transplantlibrary.com
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transplant Surgery, University Hospitals Coventry & Warwickshire, Coventry, United Kingdom.
- Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
- Oxford Transplant Centre, Churchill Hospital, Oxford, United Kingdom.
Zitieren
APA
O'Callaghan, J. M., Knight, S., & Mentor, K. (2024). Transplant Trial Watch. Transplant International. https://doi.org/10.3389/ti.2024.13746
Vancouver
O'Callaghan JM, Knight S, Mentor K. Transplant Trial Watch. Transplant International. 2024. doi:10.3389/ti.2024.13746
BibTeX
@article{OCallaghan2024,
author = {O'Callaghan, John M and Knight, Simon and Mentor, Keno},
title = {Transplant Trial Watch},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.13746}
}
EUVIMED